esmartVeröffentlicht am: 1. Okt. 2016
Landmark trial results mean pembrolizumab could become a new option for patients with NSCLC (PD-L1 ≥50%)
The first trial studying pembrolizumab first line to platinum-based chemotherapy, KEYNOTE-024, found significant benefits in both PFS and OS. “In my opinion this was a landmark trial; this will change our treatment algorithms in patients with NSCLC,” Dr Martin Reck, Chief Oncology Physician, Lung Clinic Grosshansdorf, Germany, stated at the European Society for Medical Oncology Congress 2016.